We are pleased to announce that F1 Pharma S.A. is a silver sponsor and a participant of international conference INTERDISCIPLINARY CONFERENCE ON DRUG SCIENCES ACCORD 2022 „Synergy of...
On 30 October 2019 the Chief Pharmaceutical Inspectorate granted a new Manufacturing Authorisation for F1 Pharma S.A.
As a result of the transformation of F1 Pharma into a joint stock company, we submitted a request to the Chief Pharmaceutical Inspectorate for the amendment of our Manufacturing Authorisation.
F1 Pharma successfully completed project granted by the National Center of Research and Development in Fast Track programme fulfilling both scientific and financial targets.
We are happy to inform that the project of “The development of innovative forms of mucolytic drugs, suitable for application to children, elderly persons and persons suffering from esophageal dysphagia”, funded by the National Centre for Research and Development (NCBiR), under the R&D Business Projects scheme, has been completed, accepted and financially concluded with the NCBiR.